Deltec Asset Management LLC Takes $1.44 Million Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Deltec Asset Management LLC bought a new position in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) in the 4th quarter, Holdings Channel.com reports. The firm bought 150,000 shares of the company’s stock, valued at approximately $1,440,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PSTX. The Manufacturers Life Insurance Company boosted its stake in Poseida Therapeutics by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,520 shares of the company’s stock worth $83,000 after purchasing an additional 3,552 shares during the period. Brooklyn Investment Group purchased a new position in Poseida Therapeutics during the fourth quarter valued at $40,000. SG Americas Securities LLC increased its holdings in Poseida Therapeutics by 25.4% in the 4th quarter. SG Americas Securities LLC now owns 30,623 shares of the company’s stock valued at $294,000 after acquiring an additional 6,206 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Poseida Therapeutics by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock worth $1,749,000 after purchasing an additional 9,672 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Poseida Therapeutics during the 2nd quarter valued at about $31,000. Institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Price Performance

Shares of Poseida Therapeutics stock opened at $9.50 on Wednesday. The stock has a market cap of $928.85 million, a price-to-earnings ratio of -15.08 and a beta of 1.63. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. The stock has a 50 day moving average price of $9.47 and a 200-day moving average price of $5.26. Poseida Therapeutics, Inc. has a one year low of $1.87 and a one year high of $9.67.

Poseida Therapeutics (NASDAQ:PSTX) last announced its earnings results on Thursday, November 7th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.63. Poseida Therapeutics had a negative net margin of 40.28% and a negative return on equity of 72.26%. The business had revenue of $71.75 million for the quarter, compared to the consensus estimate of $15.00 million. Equities analysts expect that Poseida Therapeutics, Inc. will post -1.02 EPS for the current year.

Insider Activity

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total transaction of $278,100.00. Following the transaction, the chairman now directly owns 651,291 shares in the company, valued at $6,037,467.57. This trade represents a 4.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 target price (down from $20.00) on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Cantor Fitzgerald cut Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 26th. Piper Sandler lowered shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 target price for the company. in a report on Monday, December 2nd. BTIG Research restated a “neutral” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Finally, William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $9.50.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.